People: NeurogesX Inc (NGSX.PK)
NGSX.PK on OTC Markets Group
0.01USD
17 Jun 2013
0.01USD
17 Jun 2013
Price Change (% chg)
$-0.00 (-25.90%)
$-0.00 (-25.90%)
Prev Close
$0.01
$0.01
Open
$0.01
$0.01
Day's High
$0.01
$0.01
Day's Low
$0.01
$0.01
Volume
4,517
4,517
Avg. Vol
269,089
269,089
52-wk High
$0.41
$0.41
52-wk Low
$0.01
$0.01
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Gary Lyons |
62 | 2011 | Executive Chairman of the Board |
Ronald Martell |
50 | 2012 | President, Chief Executive Officer, Director |
Stephen Ghiglieri |
50 | 2010 | Chief Financial Officer, Chief Operating Officer, Executive Vice President |
Stephen Peroutka |
58 | 2011 | Chief Medical Officer, Executive Vice President |
Anthony DiTonno |
64 | 2011 | Director |
Bradford Goodwin |
58 | 2009 | Independent Director |
Neil Kurtz |
61 | 2006 | Independent Director |
Robert Nelsen |
49 | 2000 | Independent Director |
John Orwin |
48 | 2009 | Independent Director |
Biographies
| Name | Description |
|---|---|
Gary Lyons |
Mr. Gary A. Lyons is Executive Chairman of the Board of NeurogesX Inc. Mr. Lyons has served as a director of Neurocrine Biosciences since February 1993 and also served as Neurocrine Biosciene’s President and Chief Executive Officer from February 1993 through January 2008. Previously, Mr. Lyons held a number of senior management positions at Genentech, Inc. including Vice President of Business Development and Vice President of Sales, and had operating responsibility at Genentech Canada and Genentech Japan. Mr. Lyons currently serves on the Boards of Directors for Rigel Pharmaceuticals, Inc., Vical, Inc., and KaloBios Pharmaceuticals. He was a former founding board member of Facet Biotech Corporation, which was sold to Abbott in April 2010. Mr. Lyons holds a B.S. in marine biology from the University of New Hampshire and a Masters of Management from Northwestern University’s J.L. Kellogg Graduate School of Management. |
Ronald Martell |
Mr. Ronald A. Martell is President, Chief Executive Officer, Director of NeurogesX Inc. He joined the Company in January 2012 as President and Chief Executive Officer, and a member of the Board of Directors. Prior to joining the Company, Mr. Martell served as Chief Executive Officer of Poniard Pharmaceuticals, Inc., a biopharmaceutical company, from February 2010 to December 2011, and served as President and Chief Operating Officer of Poniard from May 2007 to February 2010. From November 1998 to August 2006, Mr. Martell served as Vice President, Marketing and then Senior Vice President, Commercial Operations of ImClone Systems Incorporated, a biopharmaceutical company acquired by Eli Lilly and Company, where he was responsible for overseeing the company’s sales, marketing, and project and alliance management. From 1988 to 1998, Mr. Martell served in a variety of positions at Genentech, Inc., most recently as Group Manager, Oncology Products. Mr. Martell is currently the chairman of the board of Poniard. |
Stephen Ghiglieri |
Mr. Stephen F. Ghiglieri is Chief Financial Officer, Chief Operating Officer, Executive Vice President of NeurogesX Inc. He has served as the Company’s Executive Vice President, Chief Operating Officer and Chief Financial Officer since January 2010, prior to which he served as the Company’s Chief Financial Officer since October 2003. From December 2002 to October 2003, Mr. Ghiglieri served as Chief Financial Officer of Hansen Medical, Inc., a medical device company. From March 2000 to April 2002, Mr. Ghiglieri served as Executive Vice President, Chief Financial Officer and Corporate Secretary of Avolent, Inc., a software company. From July 1999 to 2000, Mr. Ghiglieri served as Vice President, Finance, Chief Financial Officer and Corporate Secretary of Andromedia, Inc., a software company. From 1994 to 1999, Mr. Ghiglieri served as Vice President, Finance and Administration, Chief Financial Officer and Corporate Secretary of Oacis Healthcare Systems, Inc., a healthcare technology company. From 1992 to 1994, Mr. Ghiglieri served as Controller of Oclassen Pharmaceuticals, Inc., a pharmaceutical company. From 1984 to 1992, Mr. Ghiglieri served as an audit manager of PricewaterhouseCoopers, LLP. Mr. Ghiglieri received a B.A. in business administration from California State University, Hayward. Mr. Ghiglieri is also a Certified Public Accountant (inactive). |
Stephen Peroutka |
Dr. Stephen J. Peroutka, M.D., Ph.D., is Chief Medical Officer, Executive Vice President of NeurogesX Inc. He has served as the Company’s Executive Vice President and Chief Medical Officer since November 2011. Prior to joining the Company, and since 2008, Dr. Peroutka served as Vice President, Scientific Affairs, at PRA, a global clinical research organization. From November 2007 to July 2008, he was Chief Medical Officer at Zogenix, Inc., a pharmaceutical company. From August 2005 to October 2007, Dr. Peroutka held positions of increasing responsibility at Johnson & Johnson, serving most recently as a Medical and Business Strategy Leader, where he was focused on the strategic assessment of pain products in the development pipeline. From 1990 to 2005, he held various positions at Synergia Pharma, Inc., Deltagen, Collabra Pharma, Spectra Biomedical, Inc. and Genentech, Inc. Dr. Peroutka is a board certified neurologist and, from 1988 to 1990, was Chief, Neurology Service, at the Palo Alto Veterans Administration Hospital. From 1984 to 1990, he was an Assistant Professor of Neurology and Pharmacology at Stanford University. Dr. Peroutka received his M.D. and Ph.D. degrees from the John Hopkins University School of Medicine, and received his B.A. degree from Cornell University. |
Anthony DiTonno |
Mr. Anthony A. DiTonno is Director of NeurogesX Inc. He served as the Company’s Chief Executive Officer, President and a director from August 2003 until December 2011, prior to which he served as the Company’s Chief Operating Officer beginning in April 2003. Mr. DiTonno serves as director of Oxygen Biotherapeutics, Inc., a publicly-held biopharmaceutical company. From October 2000 to November 2002, Mr. DiTonno served as Executive Vice President of Sales and Marketing for Enteric Medical Technologies, Inc., a medical device company. From 1997 to 2000, Mr. DiTonno served as Chief Executive Officer of LifeSleep Systems, Inc., a medical device company. From 1989 to 1997, Mr. DiTonno held various positions at Oclassen Pharmaceuticals, Inc., a pharmaceutical company, most recently as its Vice President and General Manager. Mr. DiTonno received a B.S. in business administration from St. Joseph’s University and an M.B.A. from Drexel University. |
Bradford Goodwin |
Mr. Bradford S. Goodwin is Independent Director of NeurogesX Inc. He has served as a member of the Company’s Board of Directors and Audit Committee chairman since August 2009. Since February 2010, Mr. Goodwin has served as Chief Executive Officer of CharlestonPharma, LLC, a monoclonal antibody company, and, since July 2008, Mr. Goodwin has served as President and Chief Executive Officer of Keren Pharmaceutical, Inc., an oligonucleotide focused biotechnology company. From December 2001 to December 2006, Mr. Goodwin served as Chief Executive Officer and a member of the Board of Directors of Novacea, Inc., a publicly-held biopharmaceutical company (subsequently acquired by Transcept Pharmaceuticals). From March 2000 to July 2001, Mr. Goodwin served as President, Chief Operating Officer and Founder of Collabra Pharma, a drug development company. From March 1987 to March 2000, Mr. Goodwin held various positions at Genentech, Inc., a biotechnology company and wholly-owned subsidiary of Roche Group, including most recently Vice President of Finance. Mr. Goodwin currently serves on the board of Rigel Pharmaceuticals, Inc., a publicly-held biotechnology company. Mr. Goodwin received a B.S. in Business Administration from the University of California at Berkeley. Mr. Goodwin is also a Certified Public Accountant (inactive). |
Neil Kurtz |
Dr. Neil M. Kurtz, M.D. is Independent Director of NeurogesX Inc. He has served as a director of the Company since January 2006. Since August 2008, Dr. Kurtz has served as President and Chief Executive Officer of Golden Living, a healthcare services company. Since April 2002 Dr. Kurtz has served as a member of the board of directors for Medidata, a publicly-held clinical development software company. From April 2002 to August 2008, Dr. Kurtz served as President and Chief Executive Officer and director of TorreyPines Therapeutics, Inc., a biopharmaceutical company. From September 1999 to April 2002, Dr. Kurtz was President of Worldwide Clinical Trials, a healthcare solutions company. Dr. Kurtz received a B.A. in psychology from New York University and an M.D. from the Medical College of Wisconsin. |
Robert Nelsen |
Mr. Robert T. Nelsen M.D. is Independent Director of NeurogesX Inc. He has served as a director of the Company since July 2000. Mr. Nelson was a co-founder of ARCH Venture Partners, a venture capital firm, and, since July 1994, Mr. Nelsen has served as managing director of ARCH. From April 1987 to July 1994, Mr. Nelsen served as a senior manager of ARCH Development Partners LLC, a venture capital fund. Mr. Nelsen also serves as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute for Systems Biology, and is a director of the National Venture Capital Association. Mr. Nelsen received a B.S. in biology and economics from the University of Puget Sound and an M.B.A. from the University of Chicago. |
John Orwin |
Mr. John A. Orwin is Independent Director of NeurogesX Inc. He has served as a director of the Company since November 2009. In February 2011, Mr. Orwin became Chief Executive Officer of Affymax, a publicly-held biopharmaceutical company, which he joined in April 2010 to serve as President and Chief Operating Officer. Mr. Orwin has been serving as a member of the Board of Directors of Affymax since February 2011. From January 2005 to April 2010, Mr. Orwin served at Genentech, Inc. where he served as Senior Vice President, BioOncology Business Unit since 2007. From 2001 to 2004, Mr. Orwin achieved increasing responsibility at Johnson & Johnson, up to Franchise Vice President at Tibotec Therapeutics, a division of Centocor Ortho Biotech Products, L.P. Previous positions included Senior Director, Oncology Marketing at ALZA Pharmaceuticals (acquired by Johnson & Johnson); Vice President, Marketing at Sangstat Medical Corporation; Marketing Director, Asthma at Rhône-Poulenc Rorer Pharmaceuticals and Product Manager, Schering Oncology/Biotech at Schering-Plough Corporation. Mr. Orwin received a B.A. in economics from Rutgers University and an M.B.A. from the Stern School of Business, New York University. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Gary Lyons |
-- |
Ronald Martell |
-- |
Stephen Ghiglieri |
1,239,720 |
Stephen Peroutka |
285,452 |
Anthony DiTonno |
1,786,430 |
Bradford Goodwin |
-- |
Neil Kurtz |
-- |
Robert Nelsen |
-- |
John Orwin |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Gary Lyons |
0 | 0 |
Ronald Martell |
0 | 0 |
Stephen Ghiglieri |
12,000 | 15,600 |
Stephen Peroutka |
0 | 0 |
Anthony DiTonno |
21,667 | 20,584 |
Bradford Goodwin |
0 | 0 |
Neil Kurtz |
0 | 0 |
Robert Nelsen |
0 | 0 |
John Orwin |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
MARTELL RONALD A |
25,000 | $0.00 |
GHIGLIERI STEPHEN F |
3,750 | $0.00 |
PEROUTKA STEPHEN J |
18,750 | $0.00 |
GHIGLIERI STEPHEN F |
15,000 | $0.25 |
MARKELS MICHAEL |
15,000 | $0.25 |
GOODWIN BRADFORD S |
20,000 | $1.01 |
BREEN DORON |
82,109 | $2.00 |
ARKIN MOSHE |
82,109 | $2.00 |
ARKIN MOSHE |
81,359 | $2.15 |
BREEN DORON |
81,359 | $2.15 |
MARKELS MICHAEL |
29,069 | $1.65 |
GOODWIN BRADFORD S |
60,000 | $1.65 |
BIENAIME JEAN JACQUES |
11,627 | $1.65 |
GHIGLIERI STEPHEN F |
29,069 | $1.65 |
NELSEN ROBERT T |
1,744,186 | $1.65 |
ARCH VENTURE FUND V L P |
1,744,186 | $1.65 |
BREEN DORON |
1,079 | $2.10 |
ARKIN MOSHE |
1,079 | $2.10 |
ARKIN MOSHE |
7,499 | $2.10 |
BREEN DORON |
7,499 | $2.10 |
BREEN DORON |
50,000 | $2.09 |
ARKIN MOSHE |
50,000 | $2.09 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
